Early-Stage Trial of Nivolumab in Advanced Liver Cancer - European Medical Journal

Early-Stage Trial of Nivolumab in Advanced Liver Cancer

Urology

Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%.

Presented by Anthony B. El-Khoueiry, MD, University of Southern California Norris, Comprehensive Cancer Center, Los Angeles, CA at ASCO 2015, Chicago, IL

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>